文献速递乳腺乳腺X线US

COVID-19疫苗接种后筛查乳腺X线摄影中疫苗相关淋巴结病的发生率、出现时间及长期结局

Incidence, Timing, and Long-Term Outcomes of COVID-19 Vaccine-Related Lymphadenopathy on Screening Mammography.
PubMed 文献 · J Am Coll Radiol · 2024-03-08

这项回顾性多中心研究纳入2021年2月8日至2022年1月31日接受筛查乳腺X线摄影且有至少1年随访的连续患者,评估接种COVID-19疫苗后同侧腋窝淋巴结病的发生率、时间及结局。结果显示,44,473例女性中90.0%接种疫苗,0.2%出现单侧腋窝淋巴结病,发生率在接种后1、2、3周从2.1%降至0.9%再降至≤0.5%并持续至36周;1年随访无恶性肿瘤诊断。作者认为接种后6个月内筛查发现的孤立性单侧腋窝淋巴结病可安全评估为良性。

要点

  • 接种COVID-19疫苗后筛查乳腺X线摄影中,单侧腋窝淋巴结病发生率为0.2%(94/44,473)。
  • 淋巴结病在接种后1至191天出现,中位13.5天(四分位距5.0-31.0天)。
  • 发生率在接种后1、2、3周从2.1%降至0.9%再降至≤0.5%,并持续至36周(P < .001)。

核心结论

  • 接种COVID-19疫苗后6个月内筛查乳腺X线摄影发现的孤立性单侧腋窝淋巴结病可安全评估为良性。

研究设计与样本

  • 回顾性多中心研究,纳入2021年2月8日至2022年1月31日接受筛查乳腺X线摄影且有至少1年随访的连续患者44,473例,来自五个中心,平均年龄60.4 ± 11.4岁;通过区域登记获取疫苗接种状态和制造商。

关键影像表现/征象

  • 筛查乳腺X线摄影显示接种同侧单侧腋窝淋巴结病(UIAL),94例(0.2%)出现,发生于接种后1至191天(中位13.5天,四分位距5.0-31.0天)。
  • 94例中77例(81.9%)在筛查时为BI-RADS 1或2,17例(18.1%)为BI-RADS 0。
  • 17例BI-RADS 0患者诊断性检查中,13例(76.5%)为BI-RADS 1或2,2例(11.8%)为BI-RADS 3,2例(11.8%)为BI-RADS 4;两例BI-RADS 4患者均为恶性状态且同侧乳腺恶性肿瘤。
  • 2例BI-RADS 3患者随访中,1例活检结果为良性病因,1例降级为BI-RADS 2。

诊断标准与关键数值

  • 近期(≤6周)接种疫苗情况下,UIAL通常被认为良性(BI-RADS 1或2);若伴有乳腺发现或接种后>6周识别,则评为BI-RADS 0(建议超声)。
  • 接种后1、2、3周UIAL发生率从2.1%降至0.9%再降至≤0.5%,并持续至36周(P < .001)。
  • UIAL发生率在不同疫苗制造商间无差异(P = .15)。
  • 94例UIAL患者1年随访均未诊断为恶性肿瘤。

临床应用与阅片要点

  • 筛查乳腺X线摄影报告时,若发现孤立性单侧腋窝淋巴结病且患者6个月内接种过COVID-19疫苗,可安全评估为良性。
  • 若淋巴结病伴有乳腺发现或接种后超过6周才识别,应评为BI-RADS 0并建议超声。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To determine the incidence, timing, and long-term outcomes of unilateral axillary lymphadenopathy ipsilateral to vaccine site (UIAL) on screening mammography after COVID-19 vaccination.

METHODS: This retrospective, multisite study included consecutive patients undergoing screening mammography February 8, 2021, to January 31, 2022, with at least 1 year of follow-up. UIAL was typically considered benign (BI-RADS 1 or 2) in the setting of recent (≤6 weeks) vaccination or BI-RADS 0 (ultrasound recommended) when accompanied by a breast finding or identified >6 weeks postvaccination. Vaccination status and manufacturer were obtained from regional registries. Lymphadenopathy rates in vaccinated patients with and without UIAL were compared using Pearson's χ2 test.

RESULTS: There were 44,473 female patients (mean age 60.4 ± 11.4 years) who underwent screening mammography at five sites, and 40,029 (90.0%) received at least one vaccine dose. Ninety-four (0.2%) presented with UIAL, 1 to 191 days postvaccination (median 13.5 [interquartile range: 5.0-31.0]). Incidence declined from 2.1% to 0.9% to ≤0.5% after 1, 2, and 3 weeks and persisted up to 36 weeks (P < .001). UIAL did not vary across manufacturer (P = .15). Of 94, 77 (81.9%) were BI-RADS 1 or 2 at screening. None were diagnosed with malignancy at 1-year follow-up. Seventeen (18.1%) were BI-RADS 0 at screening. At diagnostic workup, 13 (76.5%) were BI-RADS 1 or 2, 2 (11.8%) were BI-RADS 3, and 2 (11.8%) were BI-RADS 4. Both BI-RADS 4 patients had malignant status and ipsilateral breast malignancies. Of BI-RADS 3 patients, at follow-up, one was biopsied yielding benign etiology, and one was downgraded to BI-RADS 2.

DISCUSSION: Isolated UIAL on screening mammography performed within 6 months of COVID-19 vaccination can be safely assessed as benign.

来源:J Am Coll Radiol,查看原文。版权归原作者所有。

引用

  1. Lamb LR, Mercaldo SF, Carney A, et al. Incidence, Timing, and Long-Term Outcomes of COVID-19 Vaccine-Related Lymphadenopathy on Screening Mammography. J Am Coll Radiol. 2024. PMID: 38461917. doi:10.1016/j.jacr.2024.02.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。